{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:10:52Z","timestamp":1770822652720,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T00:00:00Z","timestamp":1288656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The current study was conducted to compare simultaneously obtained bone marrow (BM) cytogenetics (CTG), peripheral blood (PB) and BM fluorescence in situ hybridization (FISH), and quantitative real\u2010time polymerase chain reaction (Q\u2010PCR) for BCR\u2010ABL1 in monitoring response to treatment with tyrosine kinase inhibitors and homoharringtonine (HHT) in patients with chronic myeloid leukemia (CML).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>PB and BM FISH (n = 112 samples) and\/or Q\u2010PCR (n = 132 samples) for BCR\u2010ABL1 were simultaneously obtained in 70 patients with Philadelphia chromosome\u2010positive (Ph+) CML in chronic (68%), accelerated (16%), and blast phase (16%) before the initiation of therapy and during the course of treatment with imatinib (IM) (n = 40 patients), dasatinib (n = 20 patients), nilotinib (n = 4 patients), bosutinib (n = 18 patients), or HHT (n = 4 patients) for patients with newly diagnosed (n = 13 patients), IM\u2010sensitive (n = 34 patients), IM\u2010resistant (n = 30 patients), or IM\u2010intolerant (n = 9 patients) disease. Eighteen patients were found to have Ph+ variants or karyotypic abnormalities in addition to the Ph+.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Excellent correlations (r) were observed between PB and BM FISH (r = 0.95) and PB and BM Q\u2010PCR (r = 0.87), as well as BM CTG and PB FISH (r = 0.89) and PB Q\u2010PCR (r = 0.82). This correlation was not affected by the presence of the Ph+ variant or additional chromosomal abnormalities, the presence of <jats:italic>ABL1<\/jats:italic> kinase domain mutations, phase of the disease, or treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>PB FISH and Q\u2010PCR appear to be reliable methods with which to monitor response to modern therapy in patients with all phases of CML. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25678","type":"journal-article","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T00:36:28Z","timestamp":1288744588000},"page":"1245-1252","source":"Crossref","is-referenced-by-count":16,"title":["Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second\u2010line agents, and beyond"],"prefix":"10.1002","volume":"117","author":[{"given":"Lisa","family":"Lima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Bernal\u2010Mizrachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Saxe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen P.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mourad","family":"Tighiouart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Heffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"McLemore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Langston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott","family":"Winton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna Jean","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24325"},{"key":"e_1_2_7_6_2","first-page":"837","article-title":"et al","volume":"112","author":"Kantarjian H","year":"2008","journal-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer."},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.2000.18.7.1533","article-title":"Fluorescence in situ hybridization on peripheral\u2010blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia","volume":"18","author":"Le Gouill S","year":"2000","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_8_2","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR\u2010ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic\u2010phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian HM","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(02)00558-7"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.4.1549.bloodjournal8741549"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03705.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11910"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600783551"},{"key":"e_1_2_7_14_2","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_7_15_2","unstructured":"National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Version 1. Fort Washington PA: National Comprehensive Cancer Network;2009. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf. Accessed in 2009."},{"key":"e_1_2_7_16_2","unstructured":"2005 S. Karger Basal Switzerland L Shaffer N Tommerup An International System for Human Cytogenetic Nomenclature"},{"key":"e_1_2_7_17_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.6004\/jnccn.2009.0066","article-title":"New agents in the treatment of chronic myelogenous leukemia","volume":"7","author":"Pinilla\u2010Ibarz J","year":"2009","journal-title":"J Natl Compr Canc Netw."},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.427"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-4-199502150-00003"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.436"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173674"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V92.7.2315","article-title":"A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia","volume":"92","author":"Buno I","year":"1998","journal-title":"Blood."},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-229864"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11729"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403399"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(03)00176-0"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2790"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.419"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12588"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25678","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:24:58Z","timestamp":1760300698000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,2]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,3,15]]}},"alternative-id":["10.1002\/cncr.25678"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25678","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,2]]}}}